with many cardiovascular risk factors, including high-density lipoprotein-cholesterol, triglycerides, body mass index, von Willebrand factor, and D-dimer, 10, 11 and particularly with other inflammation markers like CRP. [12] [13] [14] Therefore, based on observational studies, it is uncertain whether the IL-6-CHD association is causal.
The translation of the current experimental and observational findings into preventive strategies has been hampered by uncertainty about the causal relationship. An alternative way to investigate the causal role of IL-6 is through its genetic determinants, using the principle of Mendelian randomization. 15 This requires the use of single-nucleotide polymorphisms (SNPs) that associate with the biomarker of interest (in this case IL-6). Several genome-wide association studies (GWAS) have identified genetic variants associated with other inflammation markers, such as CRP. [16] [17] [18] [19] [20] [21] However, there has been only 1 genome-wide association analysis for IL-6 levels in European populations to date. 22 The SardiNIA study, comprising 6145 individuals, found a significant association between SNPs in the ABO gene and IL-6 levels (P=2.6910 29 ), as well as an association with a variant in the IL6R gene (P=2.3610 8 ), which encodes the IL-6 receptor. 22 However, no additional loci were identified for circulating IL-6 levels, despite a reported heritability estimate for IL-6 of 0.61 (compared with 0.22 for CRP), 23 suggesting substantial, and largely unidentified, genetic contribution. Previous candidate gene studies of variants in the IL6 gene itself, including rs10499563 (6331T>C), rs1800795 (174G>C), and rs1800796 (572G>C), have been inconsistent, and the magnitude of reported associations has been modest at best. 24, 25 In this study, we used the IBC HumanCVD BeadChip 26 with a coverage of 48 032 SNPs in >2000 genes implicated in cardiovascular disease risk to identify genetic variants associated with the plasma concentrations of IL-6 in the Whitehall II (WHII) study and the British Women's Heart and Health Study (BWHHS). We also investigated the relationship of these variants/loci with the levels of CRP and with a range of cardiometabolic and autoimmune disorders and traits. In addition, we assessed the proportion of variance in IL-6 explained by IL-6-associated SNPs and compared that with the proportion of variance in CRP explained by variants previously shown to be associated with CRP. 20
Methods

Study Population and Phenotyping of IL-6 and CRP
The WHII study recruited 10 308 participants (70% men) between 1985 and 1989 from London-based Civil Service Departments. 27, 28 Details of blood samples, design, and participants of WHII are reported elsewhere. 29 Fasting serum was collected and stored at 70C. CRP was measured using a high-sensitivity immunonephelometric assay with a BN ProSpec nephelometer (Siemens, Frimley, United Kingdom). IL-6 was measured using a high-sensitivity ELISA (R&D Systems, Oxford, United Kingdom). Values lower than the detection limit (0.154 mg/L for CRP and 0.08 pg/mL for IL-6) were assigned a value equal to half the detection limit.
BWHHS recruited 4286 randomly selected women aged 60 to 79 years. 30 IL-6 was measured using a high-sensitivity ELISA assay (R&D Systems). Interassay and intra-assay coefficients of variation (CVs) were 7.5% and 8.9%, respectively. CRP was measured using an ultrasensitive nephelometric assay (Siemens) with a lower limit of detection of 0.162 mg/L. Values lower than the detection limit for CRP and IL-6 were also assigned a value equal to half the detection limit.
Because acute illness can lead to substantial short-term elevations in IL-6 and CRP concentration, individuals with an IL-6 value >20 pg/mL or a CRP value >40 mg/L were excluded from the analysis in both WHII (8 and 5 individuals, respectively) and BWHHS (84 and 18 individuals, respectively). In both data sets, any individual with cardiovascular disease was excluded at baseline.
Genotyping and Quality Control
Details of the DNA extraction, genotyping, and quality control in WHII and BWHHS have been reported previously. 29 Briefly, 5592 WHII individuals studied at phase 7 (2002-2004) were genotyped using the HumanCVD BeadChip (Illumina). 26 Genotypes were called using the Illumina top allele format. In addition to exclusions based on quality controls described previously, 29 148 related individuals were removed because of high-estimated identity by descent statistics, leaving 4911 samples for further analysis. In BWHHS, 3445 individuals genotyped with the IBC array were available for analysis, providing an aggregate data set of 8356 individuals across the 2 studies with genetic data, and 7815 individuals with information on IL-6 and 8072 on CRP. A total of 36 087 SNPs exceeded our minimum minor allele frequency and call rate thresholds of >0.001 and >0.98, respectively. The genomic inflation factors (λ) for all the analyses were close to 1, indicating negligible influence from population structure or differential genotyping errors.
Association Analysis
We assessed genetic associations with IL-6 and CRP levels in 2 ways: first, by single SNP analysis and, second, by applying a multivariate genetic model constructed from multiple SNPs as described below.
Single SNP Association
Association analysis was carried out on WHII and BWHHS data separately for IL-6 and CRP levels. In both studies, distributions of IL-6 and CRP levels were skewed, hence values were natural logtransformed to produce normal distributions. Genotypes were coded additively as 0, 1, or 2, corresponding to the number of minor alleles per person, as implemented in PLINK, and an additive genetic model was applied with adjustment for sex (in WHII only), age, and body mass index. The corresponding P values were used to construct quantile-quantile and Manhattan plots (Figure 1 ; Figures I and II in the online-only Data Supplement). Beta coefficients from these analyses were then combined in a meta-analysis using a fixed effects model for a total of 8356 individuals using PLINK. 31 A P value threshold of P<10 4 for the reporting of statistical significance was used, which is slightly more liberal than the Bonferronicorrected threshold of 1.410 6 , corresponding to 5% experiment-wide Type I error for the 36 087 tests performed. Under the global null hypothesis of no association, we would expect 5 SNPs to be falsely declared significant using this threshold. The less stringent significance threshold reflects the gene-centric nature of the array, because the number of independent SNPs is much smaller (≈19 000 SNPs at R 2 <0.2), and there is a higher prior odds of association with the traits of interest. 26
Variable Selection and Genetic Risk Scores
To assess the best genetic predictors at each locus, a variable selection algorithm was implemented in WHII and BWHHS as follows. All SNPs with P values <10 4 from the meta-analysis were included in the regression model. The set of markers obtained was augmented for any missing genotype data using the software fastPHASE, 32 and a stepwise selection scheme using the Akaike Information Criterion 33 was implemented separately for each chromosome. The genetic model assumed an additive effect adjusting for sex, age, and body mass index as in the univariate analyses. This analysis was performed separately for IL-6 and CRP. The estimates for the proportion of the trait variance explained (r 2 ) from the most significant signals were obtained by the regression of the trait of interest on SNPs selected through variable selection after adjustment for covariates.
To assess the joint effect of carriage of multiple independently associated SNPs, we developed an IL-6 genetic risk score. The IL-6associated SNPs remaining in the model after variable selection were entered into a multivariate regression model to obtain the regression coefficients for weighted genetic risk scores. For each individual, we calculated the weighted sum of the risk allele count, whereby the risk allele is considered to be the IL-6-raising allele, and the weight for each SNP is the coefficient derived from the multivariate regression of these SNPs in WHII. The coefficients from the WHII data set were used to calculate the genetic risk scores for participants in BWHHS in a similar manner. For comparison, we calculated an unweighted risk score using these risk alleles. The unweighted genetic risk score is a simple sum of the risk alleles. The same methods were used to calculate the genetic risk score for CRP.
Results
Genetic Associations With IL-6 Concentration
The characteristics of individuals from the 2 cohorts are shown in Table 1 . After combining data from both studies ( Figure 1 ), 14 SNPs from 2 loci were associated with IL-6 levels at P<510 8 and a further 8 SNPs from 6 loci at P<10 4 ( Table 2 ). Associations between these SNPs and IL-6 levels in the individual studies are shown in Table I Thirteen SNPs in the vicinity of the IL6R gene were highly associated with IL-6 levels (P<10 8 ; Figure 2 ). One of these, rs8192284 (now annotated as rs2228145), is a nonsynonymous SNP that results in an amino acid change (Asp358Ala). The other most strongly associated SNP (P=1.210 11 ) was a variant at the TDRD10 locus (rs12740969) located 47 kb downstream of IL6R (r 2 = 0.36 with rs8192284; Figure III in the onlineonly Data Supplement). However, after conditional analysis on the rs8192284 (IL6R) variant, the association for SNP rs12740969 gave P=0.02, suggesting that this SNP in TDRD10 is probably not an independent signal for IL-6 levels. SNPs in the IL6 gene itself showed only weak association with IL-6 levels with the minimum P value observed at this locus for the SNP rs2069852 (P=1.5710 3 ).
Significant associations with IL-6 (P<10 4 ) were found for 2 SNPs at 6p21.32 near HLA-DRB1, 2 SNPs at 11q23.3 near BUD13, 1 rare SNP (minor allele frequency=0.02) at 22q12.1 near SEZ6L gene, and 1 SNP at each of IL1R1N (2q13), TRIB3 (20p13), and ABO (9q34.2). With the exception of the TDRD10 and TRIB3 loci, all other loci identified in our analysis as hits for IL-6 ( Table 2 ) have previously been For these SNPs, associations are also presented for log CRP. CHR indicates chromosome; CRP, C-reactive protein; IL-6, interleukin-6; MAF, minor allele frequency; and SNP, single-nucleotide polymorphism. receptor (sIL-6R), intercellular adhesion molecule 1 (ICAM-1), E-selectin, P-selectin, fibrinogen, and D-dimer (see Table  III in the online-only Data Supplement).
Of the SNP associations with IL-6 levels, only those variants located in the IL6R/TDRD10 loci were also associated with CRP levels at P<10 5 (Figure 3 ). Interestingly, IL6R variants associated with high IL-6 levels were associated with low-CRP levels, and vice versa ( Table 2 ; Table I in the onlineonly Data Supplement).
Genetic Associations With CRP Concentration
After combining data from both studies, 63 SNPs from 10 loci were associated with CRP levels at P<10 4 ( Table II in Six of the loci identified as hits for CRP levels in this report have been reported previously for an association with CRP (LEPR, IL6R/TDRD10, CRP, GCKR/C2orf16/ZNF512, HNF1A, and TOMM40/APOE/APOC1), and some have been reported as hits for CHD (IL6R and APOA5), autoimmune disorders, including rheumatoid arthritis (IL6R) and Crohn's disease (IL6R and GCKR), and biomarkers of inflammatory and coagulation pathways (IL6R). In contrast to loci associated with IL-6, many of the genes associated with CRP are also involved in the genetic regulation of lipid concentrations (GCKR/C2orf16/ZNF512, APOA5, HNF1A, and TOMM40/ APOE/APOC1; Tables III and IV in the online-only Data Supplement).
Genetic Risk Scores for IL-6 and CRP
Using SNPs remaining after variable selection, we derived IL-6-specific genetic risk scores from WHII data from SNPs associated with IL-6 levels at P<10 4 and applied those to BWHHS. Four SNPs rs7518199 (IL6R), rs12740969 (TDRD10), rs3134974 (HLA-DRB1), and rs596392 (SEZ6L) were included in the score (details of these are in Table V in the online-only Data Supplement). SNPs rs7518199 and rs12740969 have r 2 =0.33 and D=0.90 in WHII, and the linkage disequilibrium structure of the region on chromosome 1 in WHII is shown in Figure III in the online-only Data Supplement. The proportion of variance in log IL-6 levels explained by the combined weighted genetic risk score was 0.02 (P=2.4410 22 ) in WHII and 0.01 (P=1.910 8 ) in BWHHS (the corresponding proportions for the unweighted genetic risk score are 0.06 and 0.04, respectively). The weighted IL-6 genetic risk scores were also associated with CRP levels: P=0.03 in WHII and P=8.710 -5 in BWHHS. After combining data from WHII and BWHHS, the weighted IL-6 genetic risk score explained 0.016 of the variance in IL-6 and 0.002 of the variance in CRP (the corresponding proportions for the unweighted genetic risk score are 0.06 for IL-6 and 0.04 for CRP; Table 3 ). CRP-specific genetic risk scores were also calculated for CRP levels (in the same manner as for IL-6), and results using the HumanCVD BeadChip are consistent with those from the literature. 34 The proportion of variance in log CRP levels explained by the weighted and unweighted genetic risk scores were 0.06 (P=9.8310 -54 ) and 0.13 (P=5.8410 -62 ), respectively. Frequency and trait associations of the allele scores are shown in Figure IV 
Discussion
Following an approach that has previously successfully identified novel loci and variants for blood lipids, 29 blood pressure, 35 human height, 36 and Type 2 diabetes mellitus, 37 we conducted a gene-centric scan to identify variants associated with circulating IL-6 levels in 2 cohorts of over 8000 British men and women. The use of the HumanCVD BeadChip in the WHII study and British Women's Heart and Health Study has successfully replicated GWAS-identified loci involved in lipid metabolism, 29 and thus offers an appropriate sample in which to investigate the genetic regulation of circulating IL-6.
In the present analyses, SNPs with the strongest associations with circulating IL-6 levels were at the IL6R locus. Several variants identified at this locus were in strong linkage disequilibrium (r 2 >0.9) with a nonsynonymous SNP (Asp358Ala, rs2228145), previously shown to influence circulating IL-6 (P=2.3610 -8 ), 22 circulating soluble IL-6R (P=210 -57 ), 17 circulating CRP (P=210 -8 ), 16 fibrinogen (P=1.810 -11 ), 38 risk of CHD (P=1.5310 -5 ), 39, 40 and risk of Type 2 diabetes mellitus (P=0.007). 41 In our analyses, these SNPs were also associated with higher IL-6 levels. The IL-6 receptor exists in both membrane-bound (mIL-6r) and soluble (sIL-6r) forms, the latter principally produced by proteolytic cleavage of mIL-6r at Gly357/Asp358. 42 The Asp358Ala variant occurs at the cleavage site, resulting in increased concentration of sIL-6r 43, 44 and a corresponding attenuation of signaling via the membranebound IL-6r. The observed increase in plasma IL-6 levels, seen with carriers of the minor allele, may be attributable to the increased half-life of the cytokine when bound by the soluble receptor, with increased levels of sIL-6R produced in these individuals. 45 IL-6 signaling via mIL-6r mediates CRP and fibrinogen production (among other effects) via the JAK/ STAT3 pathway. 45 A model of the proposed mechanism of this SNP and its effects on signaling are illustrated in Figure V in the online-only Data Supplement. Our analyses only identified the IL6R locus to be convincingly associated with both circulating IL-6 and CRP levels. However, we cannot exclude the possibility of joint effects at loci examined here that could be uncovered by larger studies, or that other common effects exist in genes not studied here.
In addition to IL6R, we also note the association of a variant in SEZ6L (22q12.1) with IL-6 levels, a gene locus identified by the Wellcome Trust Case Control Consortium to be associated with coronary disease risk. 46 The variant in TDRD10 (rs12740969, 1q21.3) is directly adjacent to IL6R, and rs3741300 (BUD13 11q23.3) is in a gene cluster containing APOA1, APOC3, APOA4, APOA5, and ZNF259 previously associated by GWAS with circulating lipids and coronary artery disease, [47] [48] [49] although not with inflammatory mediators. Genome-wide studies have indicated associations of a number of the other IL-6-associated gene loci we identified, including ABO 17 and IL1RN, 17 with inflammatory mediators besides IL-6. Given the strong association of SNPs in the CRP gene with the levels of its cognate protein (CRP), we had anticipated that variants in IL6 gene (7p15.3) may exhibit a strong association with IL-6. However, none of the 37 variants at that locus included in the HumanCVD BeadChip reached our significance threshold (P<10 -4 ).
The variants identified here for their association with IL-6 account for a very modest proportion of IL-6 variance compared with those associated with CRP. The IL-6 genetic risk score explains 0.016 of variance in IL-6 and 0.002 of variance in CRP variance in the combined data sets, whereas the CRP genetic risk score is specific for CRP and explains 0.06 of the variance. Given the close relationship in the inflammatory cascade of IL-6 with CRP immediately downstream, this suggests the chief mediator between IL-6 and CRP is the IL6R gene. Because these variants only explain a modest proportion of the variance in IL-6 believed to exist, it suggests there are additional unidentified functional SNPs. The genetic score identified here provides a tool with which to evaluate the causal role of IL-6 against a range of outcomes in a Mendelian randomization analysis. However, the proportion of variance in IL-6 explained by this score is modest, suggesting that an adequately powered Mendelian randomization analysis with CHD events as an end point would need to include additional data sets. A recent study examining a genetic score for low-density lipoprotein cholesterol in the same WHII and BWHHS data sets using SNPs from the Illumina HumanCVD Beadchip found the score explained 12.77 of the variance in low-density lipoprotein-cholesterol. 50 The proportion of variance explained by the lipid gene score is much larger than the variance explained by either the IL-6 gene score or the CRP gene score. However, even for the substantially more powerful low-density lipoprotein gene score, the CHD association was marginal (risk of CHD event in WHII was 1.08 (0.75-1.56) for the top 5 of the gene score distribution compared with those in the bottom five).
A limitation of using the HumanCVD Beadchip for these analyses is that, being of a gene-centric design, it does not give genome-wide coverage. Fourteen of 21 genes associated with CRP from GWAS are represented among the 2100 genes in the HumanCVD Beadchip. Therefore, in our analyses, additional IL-6-associated loci absent from the array will not have been detected. In addition, this chip has been designed for coverage of lipid and cardiovascular genes. A newer genotyping platform such as the ImmunoChip array (Illumina), comprising around 200 000 SNPs for examining autoimmune and inflammatory diseases, may provide an opportunity to identify additional variants for IL-6. Another limitation of our study was that analyses were limited to common variants, and therefore rare variants that may be associated with IL-6 levels were not examined.
The concordance of our findings for CRP-related SNPs with previously reported loci further validates the array as a platform for investigating potential pathological mechanisms in cardiovascular disease. 26 Indeed, of the 15 genes identified here, 9 had been previously identified by GWAS, 20 and of the remaining 6 genes, 4 (TDRD10, C2orf16, ZNF412, and TOMM40) lie in the same region as previously identified genes. In addition, we found associations of SNPs in TUB, a gene that has previously been associated with body mass index in GWAS, and SNPs in APOA5, a triglyceride-associated gene, with CRP levels. SNPs in these genes have been examined in Mendelian randomization analyses, first in a cis Mendelian randomization analysis of CRP SNPs, 51 and second in a CRP gene score-based Mendelian randomization analysis of >80 000 subjects. 20 However, neither of these studies identified evidence for a causal association of CRP with CHD. We also identified novel associations of variants in HLA-DMA and SGSM1 with IL-6, although these findings require replication. In contrast to IL-6, genetic loci for CRP are also implicated in metabolic and lipid regulation, which may suggest the existence of IL-6-independent pathways for CRP regulation. The possible role of IL-6 in cardiovascular pathophysiology is attracting growing interest, 9, 39 and the value of targeting its signaling pathway as a therapeutic or preventive strategy in CVD may, therefore, be worthy of investigation. 39, 40 However, it is important to identify additional variants associated with IL-6 levels, because other consequences of reduced IL-6 signaling could be responsible for the association with decreased risk of CHD, and may also be valid therapeutic targets. Genome-wide studies have reported associations of SNPs in IL6R with risk of rheumatoid arthritis, 52 and a monoclonal antibody inhibitor of the IL-6 receptor (tocilizumab) is in clinical use for treating rheumatoid arthritis (http://www.nice.org.uk/TA247; http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm197108.htm). Reports from randomized trials of tocilizumab suggest substantial efficacy in improving symptoms, and inflammatory and radiological measures related to rheumatoid arthritis, 53 however, trials for CHD are lacking.
Conclusions
In 2 cohorts of British adults, 22 SNPs from 7 loci were associated with circulating IL-6 levels. Fourteen SNPs in the IL6R region were associated both with IL-6 and CRP, and no associations were seen between variants in IL6 itself and IL-6 levels. These findings should be interpreted in the context of our use of a candidate-based gene-centric SNP array, including genetic variants considered a priori to have potential functional effects on cardiovascular traits. Given that the protein product of the major genetic determinant of IL-6 levels (IL6R) is the target of an existing medication, and that there is an established association of that locus with altered coronary risk, IL-6 signaling seems a valuable target for further causal investigations of cardiovascular diseases. Health. The British Women's Heart and Health Study was supported by funding from the BHF (PG/07/131/24254) and the UK Department of Health Policy Research Programme. We thank all the participants and the general practitioners, research nurses, and data management staff who supported data collection and preparation.
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